Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid SAHA in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer

Inclusion Criteria:

• Patient must be 18 years or older with confirmed diagnosis of a solid tumor for which pemetrexed and cisplatin is acceptable treatment and have received no more than 2 prior systemic therapies
• Has at least 1 measurable lesion
• Has adequate blood, liver, and kidney functions
• Has not received any chemotherapy for at least 4 weeks prior to entry in this study
• Agrees to take adequate measures to prevent pregnancy as outlined in the protocol

Exclusion Criteria:

• Patient has been treated with other investigational agents with a similar anti-tumor mechanism
• Patient from Cohorts A and B has received pemetrexed or cisplatin within the past 6 months and from Cohorts C and D have received pemetrexed within the past 6 months
• Patient from Cohorts A and B has preexisting Grade 2 or higher neuropathy and from Cohorts C and D have Grade 3 or higher neuropathy
• Patient has active infection or had received IV (intravenous) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs
• Patient has HIV, hepatitis B or hepatitis C infection
• Patient is pregnant or breast feeding
• Patient has allergy to any component of the study drugs
• Patient has history of GI (gastrointestinal) surgery or conditions